Molecular Targeting Technologies, Inc. Wins Exclusive License for Novel Neuroendocrine Neoplasm Drug from NIH

Published: Oct 08, 2018

WEST CHESTER, Pa.--(BUSINESS WIRE)-- Molecular Targeting Technologies, Inc. (MTTI) announced today that the National Institute of Biomedical Imaging and Bioengineering (an Institute within the National Institutes of Health) granted MTTI an exclusive worldwide patent commercialization license. This patent estate invented by Drs. Xiaoyuan Chen and Orit Jacobson covers a radiotherapeutic (177Lu-DOTA-EB-TATE (EBTATE)) with potential uses for treating Neuroendocrine Neoplasms (NENs).

Lutathera®, an approved radiotherapeutic for NEN, clears rapidly from the body. This licensed technology overcomes the rapid clearance problem by incorporating a derivative of Evans Blue which binds to albumin and extends residence time thus enabling smaller and less frequent dosing.

Zhaohui Zhu, MD, Ph.D., of the Peking Union Medical College Hospital, Chinese Academy of Medical Sciences who performed the clinical study commented, “EBTATE showed remarkably higher uptake and retention in neuroendocrine neoplasms,” and “our first-in-human studies1,2 demonstrated a single low-dose EBTATE treatment appears to be safe and effective in the treatment of NENs.”

“We are privileged and honored to receive the exclusive worldwide patent license from NIH,” said Chris Pak, President & CEO of MTTI. “We look forward to advancing the clinical translation of this robust molecule to improve patient outcomes.”

MTTI is a privately held biotechnology company focused on the acquisition and development of novel technologies for treatment and diagnosis of disease. More information: www.mtarget.com.

1 Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors. Journal of Nuclear Medicine, published on April 13, 2018 as doi:10.2967/jnumed.118.209841

2 Response to Single Low-dose 177Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study. Theranostics 2018; 8(12): 3308-3316. doi: 10.7150/thno.25919

 

Contacts

Molecular Targeting Technologies, Inc.
Chris Pak, 610-738-7938
cpak@mtarget.com
or
Investors
Jianwei Xu, 856-428-8168
Jxu@mtarget.com

 
 

Source: Molecular Targeting Technologies, Inc.

Back to news